61 results about "Urolithin" patented technology

A nutraceutical composition, consisting of Nicotinamide Mononucleotide in a range 250-1000 mg, Spermidine in a range 0.5-10 mg, Rhodiola Rosea in a range 200-600 mg, Cacao in a range 1000-10,000 mg, L-Theanine in a range 50-200 mg, Glucosamine in a range 500-3000 mg, and Hyaluronic acid in a range 50-240 mg, or consisting of Epigallocatechin-3-gallate in a range 100-500 mg, Quercetin in a range 250-1000 mg, Resveratrol in a range 150-1000 mg, Sulforaphane in a range 1-50 mg, and Calcium Alphaketoglutarate in a range 300-2000 mg, or consisting of Microdose Lithium in a range 1-5 mg, Trimethylglycine in a range 500-2000 mg, Glutathione in a range 250-1000 mg, Fisetin in a range 100-1000 mg, Urolithin A in a range 250-2000 mg, Sodium Butyrate in a range 100-3000 mg, Berberine in a range 500-1500 mg, Apigenin in a range 50-500 mg, Cinnamon in a range 1000-6000 mg, and Malate in a range 1000-6000 mg.

The invention belongs to the field of biological medicine, and particularly relates to application of urolithin D in preparation of medicine for relieving hyperuricemia. It is found for the first time that the urolithin D can significantly reduce the level of serum uric acid, improve the expression disorder of a kidney urate transporter, efficiently relieve or treat hyperuricemia and related diseases thereof, and relieve kidney injury and fibrosis; and the compound can be used for preparing medicines for treating hyperuricemia and related diseases, is low in cost and good in safety, and has a wide application prospect.

The invention belongs to the technical field of pharmacy, and particularly relates to application of urolithin A in treating multiple organ injuries caused by sepsis. Experiments prove that the urolithin A can significantly reduce the apoptosis rate of bone marrow-derived macrophages, and can effectively relieve multi-organ injury caused by sepsis by regulating three key paths including oxidative stress, cell apoptosis and necrotic apoptosis. The application provides solid experimental basis and theoretical support for development of urolithin A as a sepsis treatment drug, and has important conversion value and clinical application prospect in the critical disease medical field.

Methylthioninium salt-containing compositions can include a methylthioninium salt and a second mitochondria-enhancing compound selected from urolithin A having a methylthioninium salt to urolithin A weight ratio from about 1:600 to about 1:4, pyrroloquinoline quinone having a methylthioninium salt to pyrroloquinoline quinone weight ratio from about 1:20 to about 50:1, tesofensine having a methylthioninium salt to tesofensine weight ratio from about 1:2 to about 100:1, or a combination thereof.

The present application relates to the technical field of extraction and utilization of chemical substances in walnut green husk, and particularly relates to a production process of urolithin A, in particular to the following steps: obtaining walnut green husk; preparing a fermentation substrate: crushing the walnut green husk into a slurry and adding a stabilizing solution, stirring uniformly and then performing ultrasonic treatment to obtain the fermentation substrate, the stabilizing solution being an aqueous solution of a compound of mercapto-beta-cyclodextrin and chitosan; first fermentation: inoculating microbial liquid A for anaerobic fermentation, then filtering and collecting the filtrate, the microbial liquid A being obtained by inoculating Bacillus velezensis and Bacillus coagulans into culture medium A respectively for activation by shaking culture and then mixing; second fermentation: inoculating microbial liquid B into the filtrate for anaerobic fermentation again, the microbial liquid B being obtained by inoculating Enterococcus faecalis into culture medium B for culture; and extraction, wherein the present application significantly improves the yield and conversion rate of urolithin A by adding the stabilizing solution to the walnut green husk and performing two-stage fermentation, and is safe, environmentally friendly and industrialized.

The invention relates to composition of urolithins comprising urolithins and pectin and formulations of urolithins, specifically chewable formulations, comprising urolithins and a gelling agent. The invention further comprises compositions and chewable formulations comprising urolithins in combination with other active ingredients and processes for the preparation of such compositions and formulations. The invention further comprises methods of using such compositions and formulations in the treatment of conditions and diseases and for the promotion of health and performance, such in the improving muscle function.

This invention relates to the field of traditional Chinese medicine analysis, and particularly to a method for determining the content of multiple components in Terminalia chebula and constructing its characteristic fingerprint spectrum. The method provided by this invention can simultaneously determine chebulin, gallic acid, 4-galloshikimic acid, 5-galloshikimic acid, punicalin (punicalin A&B), corilagin, 1,3,6-tri-O-galloyl-β-D-glucose, chebulin, urolithin M5, chebulin tannic acid, chebulin-lintannic acid, and ellagic acid in Terminalia chebula. It exhibits high sensitivity, good precision, repeatability, and stability, and can be used to detect the tannin content in the extract at each step of the tannin extraction process, as well as for related detection in the study and quality evaluation of tannin components in Terminalia chebula. It can also be used to construct the characteristic fingerprint spectrum of Terminalia chebula. This method can also be used for determining the content of tannin compounds and constructing their characteristic fingerprint spectrum in Terminalia chebula, which contains similar tannin compounds to Terminalia chebula.

The invention relates to the technical field of health-care products, and particularly discloses a roselle-containing composition and a preparation method thereof, and the roselle-containing composition comprises the following components: a roselle extract, a cocoa extract, coating protein, a fermentation compound and auxiliary materials; the added roselle extract is subjected to multi-step pretreatment, the extraction rate and stability of active ingredients are improved, and the polarity of the roselle extract can be adjusted by adopting a composite solvent for extraction, so that the bioavailability is improved; the added cocoa extract can reduce oxidation of anthocyanin, and the cocoa extract and the roselle extract are synergistically used for reducing blood fat by inhibiting lipase activity and adjusting cholesterol; the fermentation compound can generate urolithin A, pueraria peptide and perillyl alcohol to further assist in reducing blood fat, and the coating protein improves the stability and absorption efficiency of the roselle extract; the auxiliary materials can improve the bioavailability of the active components of the raw materials, and the prepared composition has the effects of inhibiting appetite, promoting lipolysis, inhibiting fat absorption and reducing blood fat through synergistic effects of all the components.

This invention provides urolithin A cocrystals, their preparation methods, compositions, and applications. Specifically, this invention provides a urolithin A cocrystal with high bioavailability, wherein the urolithin A cocrystal is selected from the group consisting of: urolithin A-proline cocrystals, urolithin A-carnitine cocrystals, urolithin A-nicotinamide cocrystals, or urolithin A-creatine cocrystals. Compared to urolithin itself, the urolithin A cocrystals of this invention exhibit high stability, a significantly lower melting point, and significantly improved solubility and bioavailability. Furthermore, the preparation method is simple, easy to control, and has good reproducibility, allowing for stable acquisition of the target cocrystal. The composition containing the cocrystal, prepared by grinding, has high yield, low cost, and is suitable for large-scale production.

The invention belongs to the technical field of medicines, and particularly relates to application of urolithin A and beta-nicotinamide mononucleotide in preparation of a medicine for treating diabetes. The invention finds that when the urolithin A and the beta-nicotinamide mononucleotide are independently used, the hypoglycemic effect on diabetic mice cannot be realized, and when the urolithin A and the beta-nicotinamide mononucleotide are jointly used, the symptoms of diabetes and insulin resistance caused by high fat diet can be remarkably improved; the glucose tolerance and the insulin tolerance are improved; meanwhile, the content of low-density lipoprotein and cholesterol in a mouse body is reduced, so that the risk of thrombus occurrence is reduced; in addition, combined medication can significantly reduce liver cell lipid accumulation and improve mitochondrial morphological abnormality. The invention provides a brand new technical scheme and experimental basis for treating diabetes caused by high fat diet and relieving insulin resistance, and has important medical application value.

The invention discloses an engineering strain for producing urolithin A and application of the engineering strain. The engineering strain contains a tannin acyl hydrolase gene tah, an esterase gene lip, a gallic acid decarboxylase gene gdo and a dopamine dehydroxylase gene ascd. The four artificially synthesized genes are jointly constructed on an escherichia coli expression vector, so that a brand-new vector containing four co-expression genes is constructed, then the brand-new vector is transferred into a chassis strain cell to realize co-expression of the four genes, and four enzymes expressed in the cell all have activity; and the obtained heavy engineering strain can stably convert the extracellular added ellagic tannin into the urolithin A, so that the whole-cell catalysis process of producing the urolithin A by taking the ellagic tannin as a substrate is realized.

Described is a composition comprising: (a) a compound of formula (I), or a salt, prodrug, metabolite or derivative thereof; (I) wherein: A, B, C, D, W, X, Y and Z are each independently selected from H and OH; and (b) one of more agents selected from agents for improving skin health, wherein the agents for improving skin health are selected from one or more of the following: (i) one or more ceramides, for example, one or more phytoceramides; (ii) a carotenoid, for example, lycopene and / or lutein; c. zinc or a salt thereof; d. astaxanthin; and optionally e. L-lysine; f. one or more NAD boosters, for example, nicotinamide and / or co-enzyme Q10; g. eggshell membrane or an extract thereof; and / or h. biotin, or a derivative thereof.

The invention relates to compositions comprising urolithins with active agents, particularly compositions comprising urolithins and agents which promote brain health and / or immune health. The invention also relates to such compositions, for use for the treatment or prevention of diseases, disorders and conditions, and for use in non-therapeutic treatments. Example of agents which promote brain health include brain protective agents (for example phosphatidylserine, phosphatidylcholine and / or choline), agents that enhance neurotransmission (for example a nootropic, for example ergothioneine, huperzine, aGPC, taurine and / or L-theanine), agents that promote neurogenesis (for example selenium); and brain essential nutrients (example Vitamin B6, B9, B12, magnesium salts, folic acid and / or L-methylfolate). Examples of agent which promote immune health include quercetin, Elderberry or an extract thereof; a selenium salt; and / or a zinc salt.

The invention provides an inulin-modified urolithin A liposome and a preparation method of gel soft sweets thereof, and the gel soft sweets comprise the following components in percentage by mass: 10% of colloid, 22% of a sweetening agent, 10% of concentrated fruit juice, 1% of an acidity regulator, 7% of the inulin-modified urolithin A liposome and 60% of purified water. The gel soft sweets prepared by the invention can improve the bioavailability of urolithin A, and meet the increasing individual diet requirements of people. In addition, the modified liposome has higher stability under high temperature, ultraviolet radiation and high ionic strength, and can be suitable for more food systems.

Provided are a probiotic composition for preventing and treating intestinal inflammation and a use thereof. The probiotic composition for preventing and treating intestinal inflammation comprises a Lactobacillus acidophilus LA85 strain and a Bifidobacterium longum subsp. BL36 strain. Provided are a new probiotic formulation method and a new strategy for preventing and treating intestinal inflammation. It has been found that the LA85 strain and the BL36 strain can cooperate with each other, promote each other, have a synergistic effect in preventing and treating intestinal inflammation, can reduce the concentrations of the pro-inflammatory cytokines TNF-α, IL-6, and IL-1β in the serum of mice, and increase the concentration of the anti-inflammatory cytokine IL-10; can increase the concentration of urolithin A in the serum of mice and significantly reduce the concentration of reactive oxygen species in the serum; and can significantly increase the levels of the intestinal barrier indicators tight junction protein-1, tight junction protein, and Claudin-1 in the serum of mice.

This invention provides a comprehensive approach to anti-aging through the enhancement of Urolithin A production by targeting specific gut bacteria with a novel formulation. By combining 2-fucosyllactose, ellagic acid, HMOs, and probiotics, the formulation not only boosts Urolithin A levels but also promotes a diverse and healthy gut microbiome, leading to improved mitochondrial function and overall health.

The invention belongs to the technical field of biological pharmacy, and particularly relates to an intestinal targeting type urolithin A water-soluble delivery system as well as a preparation method and application thereof. The intestinal targeting type urolithin A water-soluble delivery system is characterized in that an aqueous solution of zinc nitrate-polyvinylpyrrolidone and a methanol solution of 2-methylimidazole-urolithin A are subjected to ultrasonic treatment respectively and then are mixed and stirred, and ZIF-8 loaded with urolithin A is obtained; the preparation method comprises the following steps: dropwise adding a carboxymethyl beta glucan solution into a ZIF-8 dispersion liquid loaded with urolithin A, adding CaCl2, and coating the surface with a methyl beta glucan modification layer. According to the protection-targeting-synergism integrated delivery system constructed by the invention, the problems of low UA stability, poor targeting property, insufficient bioavailability and the like are solved.

The invention provides a compound of formula (I), or salt thereof, wherein: A, B, C, D, W, X, Y and Z are each independently selected from H and OH; for use in a method of enhancing or improving fertility in a male or female subject, for example, a human male subject. The invention also provides a method of enhancing or improving fertility in a subject (for example a male subject) comprising administering a compound of formula (I) to the subject, and compositions that find use in such methods.

The application provides an application of urolithin in preparation of a drug for treating thyroid cancer. Through in-vivo and in-vitro experiments, it is proved that urolithin can effectively inhibit the proliferation of thyroid cancer cells, induce the apoptosis of the thyroid cancer cells, and significantly inhibit the tumor growth in an animal model, thereby providing a new, safe and effective drug candidate for treating thyroid cancer.

The application belongs to the technical field of biological medicine, and particularly relates to a composition for improving NAD+ level and a preparation method and application thereof. The composition is prepared by compounding NMN and urolithin A. Through synergistic effect of the two, the problem of limited efficacy of single component is effectively solved. The composition can efficiently improve NAD+ level, prolong telomere length, improve sleep quality under the condition of halving the dosage, improve aging-related indexes from multiple targets and multiple dimensions, and improve product safety and economy, thereby providing a scientific basis for development of related functional products.

A powder contains xanthan gum and at least one urolithin, such as Urolithin A; and the powder can be reconstituted in a liquid such as water to form a liquid composition for oral consumption, such as a beverage. The xanthan gum can keep the majority of the at least one urolithin in suspension in the beverage. The resultant liquid composition for oral consumption is another aspect of the present disclosure, as well as methods of making the powder, making the liquid composition for oral consumption, and using the powder or liquid composition prophylactically or therapeutically.

The invention provides a biosynthesis method for preparing urolithin A. According to the biosynthesis method for preparing urolithin A, through four-step reaction, whole-enzyme synthesis of urolithin A is achieved. According to the invention, the invention also provides a whole enzyme method process for preparing urolithin A on a small scale. Compared with a chemical synthesis method or a microbial fermentation method, the whole enzyme method shows advantages in multiple aspects.

Methylthioniniom salt-containing compositions can include a methylthioninium salt and a second mitochondria-enhancing compound selected from urolithin A having a methylthioninium salt to urolithin A weight ratio from about 1 :600 to about 1 :4, pyrroloquinoline quinone having a methylthioninium salt to pyrroloquinoline quinone weight ratio from about 1:20 to about 50:1, tesofensine having a methylthioninium salt to tesofensine weight ratio from about 1 :2 to about 100: 1, or a combination thereof.

Methods of treating amyotrophic lateral sclerosis (ALS) are disclosed. Also disclosed is a method of treating C9orf72 amyotrophic lateral sclerosis (C9-ALS).

An object of the present disclosure is, at least, to provide an enzyme that dehydroxylates hydroxyl groups at predetermined positions of urolithins having hydroxyl groups at the predetermined positions, and the object can be solved by an enzyme having the following properties (1) and (2): (1) dehydroxylating a hydroxyl group at the 4-position of urolithins; and (2) in the presence of methyl viologen (MV), being activated by one or more components selected from the group consisting of: reduced nicotinamide adenine dinucleotide (NADH); reduced nicotinamide adenine dinucleotide phosphate (NADPH); flavin adenine dinucleotide (FAD); and flavin adenine mononucleotide (FMN).

The invention provides a method for efficiently producing high-purity urolithin A based on microbial fermentation, and relates to the technical field of biosynthesis and fermention.The method comprises the following steps that a strain containing dehydroxylase is activated, and a seed solution is prepared; inoculating the seed solution into an anaerobic culture medium containing ellagic acid, and fermenting under an anaerobic condition to generate urolithin A; carrying out solid-liquid separation on the fermentation liquor, separating and purifying a target product by adopting a chromatographic separation technology to obtain high-purity urolithin A, and then carrying out content and purity detection by adopting a high performance liquid chromatography. The method is green and safe in process, mild in condition, easy and convenient to operate and suitable for large-scale production, the purity of the obtained product can reach 98% or above, and the method can be widely applied to the fields of cosmetics, health care products, functional food and the like.

A nutraceutical composition, consisting of Nicotinamide Riboside in a range of 100-2000 mg or Nicotinamide Mononucleotide in a range 250-1000 mg, Spermidine in a range 0.5-10 mg, Rhodiola Rosea in a range 200-600 mg, Cacao in a range 1000-10,000 mg, L-Theanine in a range 50-200 mg, Glucosamine in a range 500-3000 mg, and Hyaluronic acid in a range 50-240 mg, or consisting of Epigallocatechin-3-gallate in a range 100-500 mg, Quercetin in a range 250-1000 mg, Resveratrol in a range 150-1000 mg, Sulforaphane in a range 1-50 mg, and Calcium Alphaketoglutarate in a range 300-2000 mg, or consisting of Microdose Lithium in a range 1-5 mg, Trimethylglycine in a range 500-2000 mg, Glutathione in a range 250-1000 mg, Fisetin in a range 100-1000 mg, Urolithin A in a range 250-2000 mg, Sodium Butyrate in a range 100-3000 mg, Berberine in a range 500-1500 mg, Apigenin in a range 50-500 mg, Cinnamon in a range 1000-6000 mg, and Malate in a range 1000-6000 mg.

In alternative embodiments, provided are compositions, including products of manufacture and kits, and methods, for or comprising administering to an individual in need thereof an inhibitor of an inhibitory immune checkpoint molecule and / or a stimulatory immune checkpoint molecule and a formulation, wherein the formulation comprises at least two different species or genera of non-pathogenic, live bacteria, and each of the non-pathogenic, live bacteria comprise non-pathogenic colony forming live bacteria, a plurality of non-pathogenic germinable bacterial spores, or a combination thereof, and optionally the non-pathogenic bacteria or non-pathogenic bacteria arising from germination of the germinable spores can individually or together metabolize urolithin A from ellagic acid, or can individually or together synthesize urolithin A.

The invention relates to composition of urolithins comprising urolithins and pectin and formulations of urolithins, specifically chewable formulations, comprising urolithins and a gelling agent. The invention further comprises compositions and chewable formulations comprising urolithins in combination with other active ingredients and processes for the preparation of such compositions and formulations. The invention further comprises methods of using such compositions and formulations in the treatment of conditions and diseases and for the promotion of health and performance, such in the improving muscle function.